



Cinqair

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: Same as Requesting Provider

Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: Same as Referring Provider Same as Requesting Provider

Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____ *kg*

Patient Height: _____ *cm*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Cinqair MR SOC SGM – 01/2022.

**CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com**

Exception Criteria Questions:

- A. Is the product being requested for the treatment of asthma?
 Yes No *If No, skip to Site of Service Questions*
- B. *The preferred products for your patient's health plan are Fasenna, Dupixent, Nucala, and Xolair.*
Can the patient's treatment be switched to the preferred product?
 Yes, *Please obtain Form for preferred product and submit for corresponding PA* No
- C. Does the patient have a documented inadequate response or intolerable adverse event to treatment with at least three of the preferred products (Dupixent, Fasenna, Nucala, Xolair)? ***ACTION REQUIRED: If 'Yes', attach supporting chart note(s).*** Yes No

Site of Service Questions (SOS):

- A. Indicate the site of service requested:
 On Campus Outpatient Hospital Off Campus Outpatient Hospital
 Home infusion, *skip to Criteria Questions* Physician office, *skip to Criteria Questions*
 Ambulatory surgical, *skip to Criteria Questions* Pharmacy, *skip to Criteria Questions*
- B. Is this request to continue previously established treatment with the requested medication?
 Yes – This is a continuation of an existing treatment
 No – This is a new therapy request (patient has not received requested medication in the last 6 months). *Skip to Clinical Criteria Questions*
- C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.*** Yes, *skip to Clinical Criteria Questions* No
- D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
ACTION REQUIRED: If Yes, please attach supporting clinical documentation.
 Yes, *skip to Clinical Criteria Questions* No
- E. Does the patient have severe venous access issues that require the use of a special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If Yes, please attach supporting clinical documentation.***
 Yes, *skip to Clinical Criteria Questions* No
- F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?
ACTION REQUIRED: If Yes, please attach supporting clinical documentation. Yes No

Criteria Questions:

- 1. What is the diagnosis? Asthma Other _____
- 2. What is the ICD-10 code? _____
- 3. What is the patient's body weight? _____ lbs or kg (*circle one*)
- 4. Will the patient receive Cinqair as monotherapy (i.e., without any other asthma medications such as inhaled corticosteroids)? Yes No
- 5. Will the patient receive Cinqair concomitantly with other biologics indicated for asthma (e.g., Dupixent, Fasenna, Nucala, Xolair)? Yes No
- 6. Is the request for continuation of therapy with Cinqair? Yes No *If No, skip to #9*

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Cinqair MR SOC SGM – 01/2022.

**CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com**

7. Is the patient currently receiving Cinqair through samples or a manufacturer's patient assistance program?
If Yes or Unknown, skip to #10. Yes No Unknown
8. Has asthma control improved on Cinqair treatment as demonstrated by a reduction in the frequency and/or severity of symptoms and exacerbations? **ACTION REQUIRED: If 'Yes', please attach supporting chart notes or medical record documentation of improved asthma control.** Yes No No further questions
9. Does the patient have inadequate asthma control (e.g., hospitalization or emergency medical care visit within the past year) despite current treatment with both of the following medications at optimized doses? **ACTION REQUIRED: If 'Yes', please attach supporting chart notes, medical records, or claims history of previous medications tried including drug, dose, frequency, and duration.** Yes No Skip to #11
- a) Inhaled corticosteroid
- b) Additional controller (long acting beta₂-agonist, leukotriene modifier, or sustained-release theophylline)
10. Prior to receiving Cinqair, did the patient have inadequate asthma control (e.g., hospitalization or emergency medical care visit within the past year) despite current treatment with both of the following medications at optimized doses? **ACTION REQUIRED: If 'Yes', please attach supporting chart notes, medical records, or claims history of previous medications tried including drug, dose, frequency, and duration.**
- Yes No
- a) Inhaled corticosteroid
- b) Additional controller (long acting beta₂-agonist, leukotriene modifier, or sustained-release theophylline)
11. What is the patient's baseline (e.g., before significant oral steroid use) blood eosinophil count in cells per microliter? **ACTION REQUIRED: Please attach supporting chart note(s) or medical record with the patient's baseline blood eosinophil count.** _____ cells per microliter Unknown
12. Is the patient dependent on systemic corticosteroids? **Action Required: Please attach supporting chart note(s) or medical record showing the patient's dependence on systemic corticosteroids.** Yes No

Step Therapy Override: Complete if Applicable for the state of Maryland.	Please Circle	
	Yes	No
Is the requested drug being used to treat stage four advanced metastatic cancer?		
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?		
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?		
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?		

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Cinqair MR SOC SGM – 01/2022.

CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com

Step Therapy Override: Complete if Applicable for the state of Virginia.	Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No
Is the preferred drug contraindicated?	Yes	No
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____

Prescriber or Authorized Signature

Date (mm/dd/yy)

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Cinqair MR SOC SGM – 01/2022.

**CVS Caremark Specialty Pharmacy • 2211 Sanders Road NBT-6 • Northbrook, IL 60062
Phone: 1-888-877-0518 • Fax: 1-855-330-1720 • www.caremark.com**